

**Integrated HIV Planning Council
Meeting Minutes
Thursday, September 14, 2017
2:00-4:00p.m.**

Office of HIV Planning, 340 N. 12th Street, Suite 320, Philadelphia, PA 19107

Present: Juan Baez, Katelyn Baron, Kevin Burns, Michael Cappucilli, Lupe Diaz, Alan Edelstein, David Gana, Pamela Gorman, Gus Grannan, Sharee Heaven, Peter Houle, Sayuri Lio, Nicole, Miller, Christine Quimby, Joseph Roderick, Samuel Romero, Coleman Terrell, Adam Thompson, Leroy Way, Lorrita Wellington, Melvin White.

Excused: Tre Alexander, Jen Chapman, Gerry Keys, Loretta Matus, Clint Steib

Absent: Henry Bennett, Johnnie Bradley, Bikim Brown, Keith Carter, Karen Coleman, Mark Coleman, Cheryl Dennis, Tiffany Dominique, Tessa Fox, Abraham Mejia, Jeannette Murdock, Ann Ricksecker, Carlos Sanchez, Nurit Shein, James Tarver, Gail Thomas.

Guests: Whitney Kerr (DOH), Caitlin Conyngham (PDPH), Erika Aaron (PDPH), Ameenah McCann-Woods (AACO), Chris Chu (AACO), Terry Smith-Flores.

Staff: Antonio Boone, Stephen Budhu, Debbie Law, Briana Morgan, Mari Ross-Russell

Call to Order: K. Baron called the meeting to order at 2:08p.m.

Welcome/Introductions: K. Baron welcomed the HIV Integrated Planning Council members and guests.

Approval of Agenda: K. Baron presented the agenda for approval. **Motion: D. Gana moved, L. Way seconded to approve the agenda. Motion Passed: All in favor.**

Approval of Minutes (August 10, 2017): K. Baron presented the August 10, 2017 minutes for approval. **Motion: L. Way moved, G. Grannan seconded to approve the August 10, 2017 minutes. Motion Passed: All in favor.**

Report of Co-Chair: None

Report of Staff:

M Ross-Russell stated there will be a change to the Ryan White Part A grants application. She explained the Planning Council will no longer submit the 10% increase budget for the new fiscal year. She clarified HRSA will not accept a proposed budget greater than 5% increase for the EMA in the Part A grant application.

M. Ross-Russell stated both Co-chairs of the Prevention committee, C. Steib and L. Matus are unable to attend, so they cannot introduce the PrEP work group as an action item on behalf of the Prevention Committee. M. Ross-Russell stated that the Prevention committee co-chairs requested C. Conyngham present the work group to the Council

Action Items:

- PrEP Workgroup

C. Conyngham introduced the PrEP work group. She reminded the Council the Prevention Committee has been looking into PrEP since 2014 and noted Truvada was approved for PrEP use by the FDA in 2012. She explained the work group would function under the Prevention Committee and the group would include any members from HIPC, or the Prevention Committee. She notified the Council the work group is specifically looking for key stakeholders in PrEP: PrEP navigators, PrEP prescribers, people living with HIV/AIDS (PLWHA), and anyone interested in advancing PrEP.

C. Conyngham reminded the Council the work group is still in the early stages of planning, therefore definitive meeting time or dates have not been set. She noted the ideal meeting time for the PrEP work group would be a time that is beneficial to key PrEP stakeholders. C. Conyngham reminded the committee the purpose of the PrEP work group was to assess community needs, and to identify some of the barriers to care.

C. Conyngham asked the Council if they had any questions. K. Baron inquired about the timeline for the PrEP work group. C. Conyngham replied the goal is to have the group meet regularly, like other committees, and to have a first meeting as soon as possible. C. Conyngham stated the specifics of meeting time were not yet finalized, and the planning process is still ongoing. G. Grannan asked if AACO was receiving any funding from Gilead, since it seemed as though the PrEP work group would be free-advertisement of PrEP. C. Conyngham replied there was no funding from any pharmaceutical companies. C. Terrell stated the Department of Public Health (PDPH) was focused on filling coverage gaps, while Gilead's focus was PrEP prescribers. He informed the committee E. Aaron was PDPH's Clinical Advisor, and they work to make sure individuals have access to PrEP and other prevention methods. C. Terrell admitted he could see how the PrEP work group can be viewed as advertisement for Gilead, but he reminded the Council the purpose of the work group was to improve community access and knowledge of PrEP. C. Terrell explained the best way to implement the work group was under the Ryan White Planning Body. L. Diaz noted another pharmaceutical company was working on a PrEP alternative and it will be available shortly. C. Conyngham stated PrEP funding opportunities would be a good discussion topic at a later meeting. She explained the funding opportunities posed great potential for community initiative programs and collaborations between PrEP providers. K. Baron stated Descovy¹ was a new alternative to Truvada, with fewer side effects. K. Baron noted the Descovy was not yet approved for PrEP use, but it has been approved by the FDA for antiretroviral treatment use.

M. White inquired if those who were low income and uninsured would have access to PrEP. C. Conyngham replied individuals who are uninsured can get PrEP through patient assistance programs². She explained the program was available to all uninsured people who have income that is less than 500% of the federal poverty line. She also stated those who are insured but have high copays can get aid up to \$3600 annually, as long as they are within 500% income of FPL.².

1. For more information use <https://www.descovy.com>
2. Referring to medical assistance plans from Gilead, for information visit <https://www.gileadadvancingaccess.com> or call 1-800-226-2056

E. Aaron explained she helps educate different providers across the Philadelphia EMA about PEP³, nPEP⁴, and PrEP. She continued to say she also ensures providers are up to date with STD testing, and prevention. She explained prevention services should not just be limited to PrEP, but should also encompass other treatments. She stated the HIV vaginal ring⁵ has been effective in early clinical studies. E. Aaron stated she believes information from the right providers can help to expose the gaps in coverage. She informed the committee throughout the year she has spoken to 7 medical clinics and 1600 people about prevention methods and from that she is able to see some of the coverage and access gaps of prevention care. She explained the PrEP work group will be able to help fix some gaps in access to care. E. Aaron stated there needs to be more clinical trials for PrEP, and other HIV prevention methods.

M. Cappucilli asked if this is a working group of a standing committee, and if the group would be open to the public. M. Ross-Russell noted all meetings are open to the public. C. Conyngham stated guests are always welcome.

Motion: The HIPC moved to approve the PrEP work group under the Prevention Committee.

Motion Passed: 18 in favor for, 0 opposed, and 3 abstentions.

Report of Committees

Executive Committee

K. Baron stated the Executive Committee has not met since the completion of their by-laws. No further report.

Finance Committee—*A. Edelstein and D. Gana, Co- Chairs.*

A. Edelstein stated the Finance Committee had not met in September, but the committee will meet again in October. No further report.

Comprehensive Planning Committee – *A. Thompson, Chair*

A. Thompson noted the committee did not meet in August and the next meeting is Thursday, September 21, 2017. No further report

Positive Committee – *K. Carter, Co-Chair*

A. Boone noted the Positive Committee Newsletter was completed, and the committee has started a Vice news series during meetings. A. Boone stated the Vice news videos related to the Opioid epidemic in Philadelphia, and the Hepatitis C epidemic.

Needs Assessment – *Gerry Keys Chair*

D. Law noted the committee did not meet. No further report

Nominations Committee – *M. Cappucilli and K. Burns, Co-Chairs*

K. Burns explained the Nomination committee recommended 8 applicants for membership. He stated the committee did not recommend other applicants at this time.

3. PEP is post exposure prophylaxis for more information about PEP visit

<https://www.cdc.gov/hiv/basics/pep.html>

4. nPEP refers to non-occupational post exposure prophylaxis. For more information about nPEP visit <https://aidsetc.org/guide/nonoccupational-postexposure-prophylaxis>

5. In reference to <http://www.aidsmap.com/Vaginal-ring-for-HIV-prevention-effective-and-acceptable/page/3080423/>

Prevention Committee–*L. Matus and C. Steib, Co-Chairs*

M. Ross-Russell stated the committee is reviewing their objectives and activities, and a work plan will be set at their next meeting.

Old Business: None.

New Business: None.

Announcements: P. Houle announced the Delaware HIV Consortium has a job opportunity for HIV Community Planning manager. He explained the salary was competitive and welcomed all to apply. He informed the committee the job and requirements were posted on indeed.com and if anyone had any further questions to contact him directly.

Adjournment: Motion: L. Diaz moved, L. Way seconded a motion to adjourn the meeting at 2:35p.m.
Motion Passed: All in Favor.

Respectfully submitted by,

Stephen Budhu, Staff

Handouts distributed at the meeting:

- Meeting Agenda
- August 10, 2017 Meeting Minutes
- OHP Calendar